Researchers have identified a potential pathway through which inflammation in rosacea might be treated.
According to the National Rosacea Society, a study by Dr Anna Di Nardo et al. has identified protein receptor TRPV4 to play a role in activating mast cells in the skin of people with rosacea.
This new discovery has built on previous research that indicated that mast cells are part of the process in which certain types of cathelicidins, which are overproduced in those with rosacea, are activated.
The researchers injected cathelicidins into mice, bred to exhibit human-like rosacea symptoms. They found increases in TRPV2 and TRPV4 and, through further tests in mouse and human mast cell cultures, found that TRPV4 regulates the inflammation caused by mast cells.
Dr Anna Di Nardo et al. also found that the protein MRGX2 is the likely pathway for TRPV4 activation, and by turning it off they could prevent the mast cells from triggering the inflammatory immune response.
Dermatologist, Dr Anna Di Nardo, said, “Although more work needs to be done, these findings suggest that potential therapies may be developed specifically to block TRPV4 as a direct means of treating or preventing inflammation in patients with rosacea.”